The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 05, 2017
Filed:
Oct. 31, 2014
Applicant:
Pitney Pharmaceuticals Pty Limited, Claremont, WA, AU;
Inventors:
David Lawson Morris, Lugarno, AU;
Mohammad Hossein Pourgholami, Penshurst, AU;
Roger Aston, Docklands, AU;
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 47/10 (2006.01); A61K 31/34 (2006.01); A61K 31/277 (2006.01); A61K 31/337 (2006.01); A61K 31/513 (2006.01); A61K 31/65 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 31/138 (2006.01); A61K 31/167 (2006.01); A61K 31/17 (2006.01); A61K 31/40 (2006.01); A61K 31/4045 (2006.01); A61K 31/4184 (2006.01); A61K 31/429 (2006.01); A61K 31/4965 (2006.01); A61K 31/5415 (2006.01); A61K 31/5513 (2006.01); A61K 31/567 (2006.01); A61K 31/585 (2006.01); A61K 31/275 (2006.01); C07C 255/29 (2006.01); C07C 323/62 (2006.01); C07C 317/44 (2006.01);
U.S. Cl.
CPC ...
A61K 31/277 (2013.01); A61K 31/138 (2013.01); A61K 31/167 (2013.01); A61K 31/17 (2013.01); A61K 31/337 (2013.01); A61K 31/40 (2013.01); A61K 31/4045 (2013.01); A61K 31/4184 (2013.01); A61K 31/429 (2013.01); A61K 31/4965 (2013.01); A61K 31/513 (2013.01); A61K 31/5415 (2013.01); A61K 31/5513 (2013.01); A61K 31/567 (2013.01); A61K 31/585 (2013.01); A61K 31/65 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 31/275 (2013.01); C07C 255/29 (2013.01); C07C 317/44 (2013.01); C07C 323/62 (2013.01);
Abstract
The present invention relates to pharmaceutical combinations comprising aminoacetonitrile derivatives and anticancer compounds. Further, the present invention relates to these pharmaceutical combinations for use in the treatment of cancer.